Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ProBioGen Signs Deal with TOP 10 Pharma Company for Therapeutic Antibody Platform

Published: Wednesday, February 20, 2013
Last Updated: Wednesday, February 20, 2013
Bookmark and Share
Another global pharma company has licensed ProBioGen’s GlymaxX® ADCC-enhancement technology.

The license covers the modification of the pharma’s antibody production platform for the generation of antibodies with enhanced potency. The continued licensing success demonstrates the industry’s endorsement of GlymaxX®. The GlymaxX® technology is highly versatile since it can be applied to any starter or production cell line. It allows both, the robust permanent modification of established antibody expression platforms, as well as the rapid conversion of existing antibody producer clones to produce ADCC-enhanced molecules.

The GlymaxX® technology is based on the stable expression of a heterologous enzyme in the antibody producing cells. GlymaxX® prevents antibody fucosylation almost completely, but moreover allows the exact adjustment of any desired fucosylation level through the controlled addition of fucose into the culture medium.

The license with an option for a commercial license covers the modification of the company’s antibody production platform and the generation of multiple antibodies with enhanced ADCC potency. Financial details are not disclosed.

The technology can be licensed royalty-free, based on milestone-dependent license fees only.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ProBioGen, Eucodis Sign Agreement
Company has signed an exclusive license agreement with Eucodis Bioscience to commercialize C-LiNK, a novel antibody drug conjugation technology.
Wednesday, April 20, 2016
ProBioGen and Tizona Therapeutics Sign Agreement
ADCC-enhancement for innovative cancer therapy, produced via ProBioGen’s accelerated CMC development path.
Tuesday, October 06, 2015
ProBioGen Signs GlymaxX ADCC Enhancement Technology License Deal
A non-exclusive commercial multi-product licensing agreement with Novartis.
Tuesday, June 24, 2014
ProBioGen and Merus Sign Deal on GlymaxX® ADCC Enhancement Technology
GlymaxX® manufacturing technology improves bispecific antibody activity for solid tumor treatment.
Wednesday, March 05, 2014
ProBioGen and Emergent BioSolutions Partner
ProBioGen announces expansion of commercial licenses with Emergent BioSolutions for AGE1.CR® viral vaccine manufacturing production platform.
Tuesday, December 17, 2013
Scientific News
Boosting Effectiveness of Asthma Therapy
A team of scientists from UCSF has developed a new treatment to dampen bronchospasm.
Immune-Cell Traps May Aid Cancer Metastasis
Study suggests cancer cells can induce neutrophils to release traps which the cells use to capture pathogens.
New Regulator of Immune Reaction Discovered
Calcium signal in cell nucleus regulates not only many brain functions but also defence reactions of the immune system.
Cell’s ‘Built-In Circuit’ Help Prevent Tumour Growth
Researchers have created cells with a 'built-in genetic circuit' that inhibits tumour growth.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Factors Behind Suppression of Stem Cell Mobilization Revealed
The findings could lead to improvements in transplantation therapy.
Common Virus Helps Fight Liver Cancer
Reovirus, a cause of childhood colds, stimulates the immune system to kill cancerous cells.
Antibody Protects Mice from Zika Infection
Researchers develop human-derived antibody protected pregnant mice and their developing fetuses from Zika infection.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
T Cell Channel Could Be Targeted to Treat Cancers
Researcher identify ion-channel found within T cells that could be targeted to reduce development of neck and head cancers.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!